aTYR PHARMA (ATYR) Other Non-Current Assets (2014 - 2026)

aTYR PHARMA (ATYR) has reported Other Non-Current Assets for 13 consecutive years, with $1.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non-Current Assets fell 47.88% year-over-year to $1.5 million; the trailing twelve-month figure through Jun 2026 stood at $1.5 million (down 47.88% YoY), and the FY2025 full-year result was $2.2 million, down 24.26% from the prior year.
• Other Non-Current Assets fell to $1.5 million in Q2 2026 per ATYR's latest filing, from $1.8 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $3.5 million in Q4 2023 and bottomed at $733000.0 in Q2 2022.
• Historically, Other Non-Current Assets has averaged $2.7 million across 5 years, with a median of $2.9 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Other Non-Current Assets soared 1317.09% in 2022, then plunged 47.88% in 2026.
• Over 5 years, Other Non-Current Assets stood at $3.2 million in 2022, then rose by 10.08% to $3.5 million in 2023, then retreated by 15.3% to $3.0 million in 2024, then declined by 24.26% to $2.2 million in 2025, then plunged by 32.89% to $1.5 million in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $1.5 million, $1.8 million, and $2.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.